Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis

Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by suppressing hepatic ketogenesis through a PPAR-dependent mechanism that downregulates HMGCS2 expression and modulates free fatty acid levels.

The Gist

The Big Problem: The "SGLT2" Glitch

Imagine your body is a high-performance hybrid car. It usually runs on gas (sugar/glucose). But when the gas tank is low, or if you are driving in a specific way that tricks the car's computer, the engine switches to burning wood chips (fats) instead.

When you burn wood chips, you get a byproduct called ketones. A little bit of wood smoke is fine; it's actually a useful backup fuel. But if you burn too much wood too fast, the exhaust fills the car with toxic smoke. This is called ketoacidosis, a dangerous condition where the blood becomes too acidic.

Recently, doctors discovered a new type of medicine for diabetes called SGLT2 inhibitors (let's call them "Sugar-Slammers"). These drugs are great because they help your body dump excess sugar through your urine. However, they have a weird side effect: they sometimes trick the body into thinking it's starving, causing it to burn fat way too fast. This leads to that toxic "smoke" (ketoacidosis), even when the person's blood sugar isn't dangerously high. It's like the car is choking on its own exhaust while the driver is still sitting in a parking lot.

The Hero: Celastrol (The "Fire Extinguisher")

Enter Celastrol. This is a natural compound found in an old Chinese medicinal plant (the "Thunder God Vine"). Scientists have known for a while that Celastrol is great at helping with obesity and inflammation. But in this study, researchers asked: Can Celastrol stop the engine from choking on its own exhaust?

The Answer: Yes! They found that Celastrol acts like a smart fire extinguisher for the liver.

How It Works: The Factory Analogy

Think of your liver as a factory.

• The Goal: The factory's job is to turn fat into energy (ketones).
• The Boss: The factory has a boss named PPARα. When the body is hungry, PPARα shouts, "Make more ketones! Burn the fat!"
• The Machine: The boss controls a giant machine called HMGCS2. This machine is the actual engine that creates the ketones.

What Celastrol Does:

1. Silences the Boss: Celastrol sneaks into the factory and puts a gag on the boss (PPARα). The boss stops shouting "Make more!"
2. Shuts Down the Machine: Because the boss is quiet, the machine (HMGCS2) slows down or stops.
3. The Result: The factory stops producing the toxic exhaust (ketones), even if the body is fasting or taking the "Sugar-Slammer" drugs.

The Experiment: Testing the Theory

The researchers tested this on mice to see if it really worked.

• The Setup: They took mice, made them diabetic, and gave them the "Sugar-Slammer" drug (Dapagliflozin). As expected, the mice started producing dangerous levels of ketones.
• The Fix: They gave some of these mice Celastrol first.
• The Outcome: The mice treated with Celastrol did not get the toxic exhaust problem. Their ketone levels stayed safe, and their blood sugar actually got a little better, too.

The "PPARα" Proof:
To be absolutely sure Celastrol was working through the "Boss" (PPARα), they used a special group of mice that were born without this boss (genetically engineered to lack PPARα).

• In these mice, Celastrol did nothing.
• This proved that Celastrol needs the boss to be there to shut him down. If the boss is already gone, Celastrol has no one to fight, and the mechanism doesn't work. This confirmed that Celastrol's power comes specifically from silencing PPARα.

Short-Term vs. Long-Term Effects

The study also noticed something interesting about timing:

• Short-Term (1-2 days): Celastrol works immediately by just silencing the liver's boss. It doesn't change how much fat the body is storing or burning from the fat cells yet. It's a direct hit on the liver.
• Long-Term (7 days): If you keep taking it, Celastrol also helps the body burn fat more efficiently overall and reduces body weight. It's like the fire extinguisher eventually helps clean up the whole garage.

Why This Matters

This is a big deal because "Sugar-Slammer" drugs are very popular for treating Type 2 diabetes. However, the fear of ketoacidosis stops some people from using them or makes doctors nervous.

This study suggests that Celastrol could be the perfect sidekick. If you take Celastrol along with the diabetes drug, it might prevent the dangerous side effect (ketoacidosis) while keeping the benefits of the drug.

The Catch (Limitations)

While the results are exciting, the researchers are careful to note a few things:

1. Toxicity: Celastrol is powerful, but in high doses, it can be toxic to the liver or nerves. It's a bit like a nuclear fire extinguisher; you have to use the right amount, or you might cause damage yourself.
2. More Research Needed: We know it works in mice, but we need to make sure it's safe and effective in humans. We also need to figure out exactly how it grabs onto the "Boss" protein so we can design even better drugs.

The Bottom Line

The researchers discovered that a natural compound called Celastrol can stop the liver from overproducing dangerous ketones. It does this by silencing a specific protein (PPARα) that acts as the "boss" of ketone production. This finding opens the door to safer ways to use popular diabetes drugs without the risk of life-threatening acidosis.

Technical Summary

1. Problem Statement

• Clinical Challenge: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used to treat Type 2 Diabetes (T2D) but carry a risk of inducing diabetic ketoacidosis (DKA), specifically euglycemic DKA (EDKA). This is a life-threatening complication characterized by metabolic acidosis and ketosis without significant hyperglycemia.
• Mechanistic Gap: SGLT2i promote lipolysis and alter the glucagon/insulin ratio, leading to excessive hepatic ketone production. While the role of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in upregulating ketogenesis is known, effective therapeutic strategies to prevent SGLT2i-induced hyperketonemia without compromising glucose control are lacking.
• Research Question: Can Celastrol (Cel), a triterpenoid with known anti-obesity and anti-diabetic properties, mitigate SGLT2i-induced hyperketonemia, and if so, what is the underlying molecular mechanism?

2. Methodology

The study employed a multi-faceted approach combining in vivo animal models, in vitro cell cultures, and molecular biology techniques:

• Animal Models:
  • Wild-type (WT) C57BL/6 mice: Used to assess the effects of Cel on fasting-induced ketogenesis and body weight.
  • $Ppar\alpha^{-/-}$ (Knockout) mice: Used to determine if PPARα is essential for Cel's anti-ketogenic effects.
  • T2D Mouse Model: Induced by High-Fat Diet (HFD) followed by low-dose Streptozotocin (STZ) injection.
  • SGLT2i-Induced Hyperketonemia Model: T2D mice were pretreated with Cel (1 mg/kg/day for 7 days) followed by an injection of Dapagliflozin (SGLT2i) and a 12-hour fasting period.
• Cell Culture: Mouse primary hepatocytes (MPH) from WT and $Ppar\alpha^{-/-}$ mice were treated with Cel (10 μM) to validate hepatic-specific mechanisms.
• Molecular & Biochemical Assays:
  • RNA-Seq: Performed on liver tissue to identify differentially expressed genes (DEGs) and pathway enrichment (GO/KEGG).
  • qPCR & Western Blotting: Quantified mRNA and protein levels of key enzymes (HMGCS2, HMGCL) and transcription factors (PPARα).
  • Molecular Docking: Used CB-Dock2 to predict the binding affinity and interaction sites between Cel and PPARα.
  • Biotinylated-Celastrol Pull-down: Confirmed direct physical interaction between Cel and PPARα in liver lysates.
  • Metabolic Measurements: Blood glucose, $\beta$-hydroxybutyrate ($\beta$-OHB), and serum Free Fatty Acids (FFAs) were measured.

3. Key Contributions

• Discovery of a Novel Mechanism: The study identifies Celastrol as a specific inhibitor of hepatic ketogenesis, acting primarily through the downregulation of PPARα.
• Time-Dependent Dual Mechanism: The research distinguishes between short-term and long-term effects:
  • Short-term (≤2 days): Cel suppresses ketogenesis by directly inhibiting PPARα expression and activity, independent of adipose tissue lipolysis.
  • Long-term (7 days): Cel reduces ketogenesis by modulating both PPARα signaling and reducing serum FFAs (via reduced adipose lipolysis and fat mass).
• Therapeutic Application: The study provides the first evidence that Cel can effectively prevent SGLT2 inhibitor-induced hyperketonemia in a diabetic mouse model, offering a potential adjunctive therapy for patients on SGLT2i.
• Target Validation: Confirms PPARα as the critical mediator, as the protective effects of Cel were completely abolished in $Ppar\alpha^{-/-}$ mice.

4. Key Results

• Attenuation of Ketogenesis: Cel treatment significantly reduced fasting-induced blood $\beta$-OHB levels in WT mice. A 7-day course (1 mg/kg/day) was particularly effective.
• Downregulation of Ketogenic Enzymes: Cel treatment led to a significant decrease in the mRNA and protein expression of HMGCS2 (the rate-limiting enzyme of ketogenesis) and HMGCL.
• PPARα Inhibition:
  • Cel reduced hepatic PPARα mRNA and protein levels.
  • Molecular Docking revealed a high-affinity interaction (Vina score: -8.2 kcal/mol) between Cel and PPARα.
  • Pull-down assays confirmed that Cel binds directly to PPARα.
• Genetic Validation: In $Ppar\alpha^{-/-}$ mice, Cel failed to reduce $\beta$-OHB levels, HMGCS2 expression, or body weight, proving the effect is PPARα-dependent.
• Lipolysis Dynamics:
  • Short-term Cel treatment did not alter serum FFAs or adipose tissue weight, indicating the anti-ketogenic effect is primarily hepatic.
  • Long-term (7 days) treatment reduced white adipose tissue (WAT) weight and serum FFAs, contributing to a secondary reduction in ketone precursors.
• SGLT2i Model Efficacy: In T2D mice, Dapagliflozin alone increased $\beta$-OHB and HMGCS2/PPARα levels. Cel preconditioning reversed these effects, lowering $\beta$-OHB and HMGCS2 without compromising the glucose-lowering efficacy of Dapagliflozin.

5. Significance and Implications

• Clinical Relevance: This study addresses a critical safety concern in diabetes management. It suggests that Celastrol could be developed as a prophylactic agent to allow patients to safely use SGLT2 inhibitors without the risk of life-threatening ketoacidosis.
• Mechanistic Insight: The findings clarify the hierarchical regulation of ketogenesis, highlighting that PPARα inhibition by Cel is sufficient to block ketone overproduction even before systemic lipid mobilization is altered.
• Therapeutic Potential: Celastrol emerges as a multi-target compound capable of improving glycemic control, reducing fat mass, and preventing metabolic acidosis.
• Future Directions & Limitations:
  • The study notes that while promising, Cel's toxicity (hepatotoxicity/neurotoxicity) at high doses or long durations must be managed.
  • Future work is needed to elucidate the precise structural binding interface of Cel-PPARα and the exact transcriptional mechanism by which Cel downregulates Pparα mRNA.
  • Pharmacokinetic and long-term safety studies in clinical settings are required before translation.

Conclusion: Celastrol effectively curbs hepatic ketone overproduction in a PPARα-dependent manner, offering a novel therapeutic strategy to mitigate SGLT2 inhibitor-induced hyperketonemia while maintaining metabolic benefits.